Sickle cell disease (SCD) is a monogenic, yet highly phenotypically variable disease with multisystem pathology. This manuscript provides an overview of many of the known determinants, modifiers, and correlates of disease severity in SCD. Despite this wealth of data, modeling the variable and multisystem pathology of SCD continues to be difficult. The current status of prediction of specific adverse outcomes and global disease severity in SCD is also reviewed, highlighting recent successes and ongoing challenges.
QuinnCTRogersZRMcCavitTLBuchananGR. Improved survival of children and adolescents with sickle cell disease. Blood2010; 115: 3447–52.
2.
TelferPCoenPChakravortySWilkeyOEvansJNewellHSmallingBAmosRStephensARogersDKirkhamF. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica2007; 92: 905–12.
3.
LêPQGulbisBDedekenLDupontSVanderfaeillieAHeijmansCHuybrechtsSDevalckCEfiraADresseM-FRozenLBenghiatFSFersterA. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer2015; 62: 1956–61.
4.
WierengaKJHambletonIRLewisNA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet2001; 357: 680–3.
5.
LanzkronSCarrollCPHaywoodC. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep2013; 128: 110–6.
6.
PlattOSBrambillaDJRosseWFMilnerPFCastroOSteinbergMHKlugPP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med1994; 330: 1639–44.
AkinsheyeIAlsultanASolovieffNNgoDBaldwinCTSebastianiPChuiDHKSteinbergMH. Fetal hemoglobin in sickle cell anemia. Blood2011; 118: 19–27.
9.
SteinbergMHChuiDHKDoverGJSebastianiPAlsultanA. Fetal hemoglobin in sickle cell anemia: a glass half full?Blood2014; 123: 481–5.
10.
MasonKPGrandisonYHayesRJSerjeantBESerjeantGRVaidyaSWoodWG. Post-natal decline of fetal haemoglobin in homozygous sickle cell disease: relationship to parenteral Hb F levels. Br J Haematol1982; 52: 455–63.
11.
TheinSLMenzelSLathropMGarnerC. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet2009; 18: R216–23.
12.
LettreGSankaranVGBezerraMACAraújoASUdaMSannaSCaoASchlessingerDCostaFFHirschhornJNOrkinSH. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A2008; 105: 11869–74.
13.
AkinsheyeISolovieffNNgoDMalekASebastianiPSteinbergMHChuiDHK. Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. Am J Hematol2012; 87: 217–9.
14.
EmburySHDozyAMMillerJDavisJRKlemanKMPreislerHVichinskyELandeWNLubinBHKanYWMentzerWC. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med1982; 306: 270–4.
15.
Ohene-FrempongKWeinerSJSleeperLAMillerSTEmburySMoohrJWWethersDLPegelowCHGillFM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood1998; 91: 288–94.
16.
DomingosIFFalcãoDAHatzlhoferBLCunhaAFSantosMNAlbuquerqueDMFertrinKYCostaFFAzevedoRCMachadoCGAraújoASLucena-AraujoARBezerraMA. Influence of the βs haplotype and α-thalassemia on stroke development in a Brazilian population with sickle cell anaemia. Ann Hematol2014; 93: 1123–9.
17.
CoxSEMakaniJSokaDL’EsperenceVSKijaEDominguez-SalasPNewtonCRJBirchAAPrenticeAMKirkhamFJ. Haptoglobin, alpha-thalassaemia and glucose-6-phosphate dehydrogenase polymorphisms and risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania. Br J Haematol2014; 165: 699–6.
18.
Joly P, Garnier N, Kebaili K, Renoux C, Dony A, Cheikh N, Renard C, Ceraulo A, Cuzzubbo D, Pondarré C, Martin C, Pialoux V, Francina A, Bertrand Y, Connes P. G6PD deficiency and absence of α-thalassemia increase the risk for cerebral vasculopathy in children with sickle cell anemia. Eur J Haematol. Epub ahead of print 13 June 2015. DOI: 10.1111/ejh.12607.
19.
MilnerPFKrausAPSebesJISleeperLADukesKAEmburySHBellevueRKoshyMMoohrJWSmithJ. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med1991; 325: 1476–81.
20.
SteinbergMHRosenstockWColemanMBAdamsJGPlaticaOCedenoMRiederRFWilsonJTMilnerPWestS. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood1984; 63: 1353–60.
21.
NouraieMReadingNSCampbellAMinnitiCPRanaSRLuchtman-JonesLKatoGJGladwinMTCastroOLPrchalJTGordeukVR. Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. Br J Haematol2010; 150: 218–25.
22.
BenkerrouMAlbertiCCouqueNHaouariZBaAMissudFBoizeauPHolvoetLIthierGElionJBaruchelADucrocqR. Impact of glucose-6-phosphate dehydrogenase deficiency on sickle cell anaemia expression in infancy and early childhood: a prospective study. Br J Haematol2013; 163: 646–54.
23.
MillerSTMiltonJSteinbergMH. G6PD deficiency and stroke in the CSSCD. Am J Hematol2011; 86: 331–331.
24.
Belisário AR, Rodrigues Sales R, Evelin Toledo N, Velloso-Rodrigues C, Maria Silva C, Borato Viana M. Glucose-6-phosphate dehydrogenase deficiency in Brazilian children with sickle cell anemia is not associated with clinical ischemic stroke or high-risk transcranial Doppler. Pediatr Blood Cancer. Epub ahead of 3 February 2016. DOI: 10.1002/pbc.25924.
25.
ThangarajhMYangGFuchsDPonisioMRMcKinstryRCJajuANoetzelMJCasellaJFBarron-CasellaEHooperWCBouletSLBeanCJPyleMEPayneABDriggersJTrauHAVendtBARodeghierMDeBaunMR. Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phosphate dehydrogenase mutation in children with sickle cell anaemia. Br J Haematol2012; 159: 352–9.
26.
BernaudinFVerlhacSChevretSTorresMCoicLArnaudCKamdemAHauIGrazia NeonatoMDelacourtC. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood2008; 112: 4314–7.
27.
AdekileAKutlarFMcKieKAddingtonAElamDHolleyLClairBKutlarA. The influence of uridine diphosphate glucuronosyl transferase 1A promoter polymorphisms, beta-globin gene haplotype, co-inherited alpha-thalassemia trait and Hb F on steady-state serum bilirubin levels in sickle cell anemia. Eur J Haematol2005; 75: 150–5.
28.
MiltonJNSebastianiPSolovieffNHartleySWBhatnagarPArkingDEDworkisDACasellaJFBarron-CasellaEBeanCJHooperWCDeBaunMRGarrettMESoldanoKTelenMJAshley-KochAGladwinMTBaldwinCTSteinbergMHKlingsES. A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. PLoS ONE2012; 7: e34741–e34741.
29.
FertrinKYMeloMBAssisAMSaadSTOCostaFF. UDP-glucuronosyltransferase 1 gene promoter polymorphism is associated with increased serum bilirubin levels and cholecystectomy in patients with sickle cell anemia. Clin Genet2003; 64: 160–2.
30.
HaverfieldEVMcKenzieCAForresterTBouzekriNHardingRSerjeantGWalkerTPetoTEAWardRWeatherallDJ. UGT1A1 variation and gallstone formation in sickle cell disease. Blood2005; 105: 968–72.
31.
PassonRGHowardTAZimmermanSASchultzWHWareRE. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol2001; 23: 448–51.
32.
AlFadhliSAl-JaferHHadiMAl-MutairiMNizamR. The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients. PLoS ONE2013; 8: e77681–e77681.
33.
ChaarVKéclardLDiaraJPLeturduCElionJKrishnamoorthyRClaytonJRomanaM. Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia. Haematologica2005; 90: 188–99.
34.
ChaouchLTalbiEMoumniIBen ChaabeneAKalaiMChaouachiDMallouliFGhanemAAbbesS. Early complication in sickle cell anemia children due to A(TA)nTAA polymorphism at the promoter of UGT1A1 gene. Dis Markers2013; 35: 67–72.
35.
QuinnCTMillerST. Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia. Hematol Oncol Clin N Am2004; 18: 1339–54.
36.
StrimbuKTavelJA. What are biomarkers?Curr Opin HIV AIDS2010; 5: 463–6.
37.
Hryniewicz-JankowskaAChoudharyPKAmmannLPQuinnCTGoodmanSR. Monocyte protein signatures of disease severity in sickle cell anemia. Exp Biol Med (Maywood)2009; 234: 210–1.
38.
MillerSTSleeperLAPegelowCHEnosLEWangWCWeinerSJWethersDLSmithJKinneyTR. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med2000; 342: 83–9.
39.
van den TweelXWvan der LeeJHHeijboerHPetersMFijnvandraatK. Development and validation of a pediatric severity index for sickle cell patients. Am J Hematol2010; 85: 746–51.
40.
JolyPPondarréCBardelCFrancinaAMartinC. The alpha-globin genotype does not influence sickle cell disease severity in a retrospective cross-validation study of the pediatric severity score. Eur J Haematol2012; 88: 61–7.
41.
AdamsRMcKieVNicholsFCarlEZhangDLMcKieKFigueroaRLitakerMThompsonWHessD. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med1992; 326: 605–10.
42.
AdamsRJMcKieVCHsuLFilesBVichinskyEPegelowCAbboudMGallagherDKutlarANicholsFTBondsDRBrambillaD. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med1998; 339: 5–11.
43.
McCavitTLXuanLZhangSFloresGQuinnCT. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatr Blood Cancer2013; 60: 823–7.
44.
WareREDavisBRSchultzWHBrownRCAygunBSarnaikSOdameIFuhBGeorgeAOwenWLuchtman-JonesLRogersZRHilliardLGaugerCPicconeCLeeMTKwiatkowskiJLJacksonSMillerSTRobertsCHeeneyMMKalfaTANelsonSImranHNottageKAlvarezORhodesMThompsonAARothmanJAHeltonKJRobertsDColemanJBonnerMJKutlarAPatelNWoodJPillerLWeiPLudenJMortierNAStuberSELubanNLCCohenARPresselSAdamsRJ. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016; 387: 661–70.
45.
NissOQuinnCTLaneADailyJKhouryPRBakeerNSkalskiEKimballTRTowbinJAMalikPTaylorMD. The unique cardiomyopathy with restrictive physiology of sickle cell disease. JACC Cardiovasc Imaging2016; 9: 244–53.
46.
GladwinMTSachdevVJisonMLShizukudaYPlehnJFMinterKBrownBColesWANicholsJSErnstIHunterLABlackwelderWCSchechterANRodgersGPCastroOOgnibeneFP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med2004; 350: 886–95.
47.
SachdevVMachadoRFShizukudaYRaoYNSidenkoSErnstISt PeterMColesWARosingDRBlackwelderWCCastroOKatoGJGladwinMT. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol2007; 49: 472–9.
48.
CabritaIZMohammedALaytonMGhorashianSGilmoreAChoGHowardJAnieKADesforgesLBassettPGrapsaJHowardLMahalingamGDawsonDPintoFJNihoyannopoulosPDaviesSCGibbsJSR. The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. Br J Haematol2013; 162: 400–8.
49.
LeeMTSmallTKhanMARosenzweigEBBarstRJBrittenhamGM. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. Br J Haematol2009; 146: 437–41.
50.
HagarRWMichlitschJGGardnerJVichinskyEPMorrisCR. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol2008; 140: 104–12.
51.
HebsonCNewTRecordEOsterMEhrlichABorderWJames-HerryAKanaanU. Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predictive than previously thought?J Pediatr Hematol Oncol2015; 37: 134–9.
52.
StylesLASchalkwijkCGAarsmanAJVichinskyEPLubinBHKuypersFA. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood1996; 87: 2573–78.
NaprawaJTBonsuBKGoodmanDGRanalliMA. Serum biomarkers for identifying acute chest syndrome among patients who have sickle cell disease and present to the emergency department. Pediatrics2005; 116: e420–5.
55.
BallasSKFilesBLuchtman-JonesLBenjaminLSwerdlowPHilliardLCoatesTAbboudMWojtowicz-PragaSKuypersFAMichael GrindelJ. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin2006; 30: 165–70.
StylesLWagerCGLabotkaRJSmith-WhitleyKThompsonAALanePAMcMahonLECMillerRRoseffSDIyerRVHsuLLCastroOLAtagaKIOnyekwereOOkamMBellevueRMillerST. Sickle Cell Disease Clinical Research Network (SCDCRN). Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol2012; 157: 627–36.
58.
QuinnCTLeeNJShullEPAhmadNRogersZRBuchananGR. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood2008; 111: 544–8.
59.
SebastianiPNolanVGBaldwinCTAbad-GrauMMWangLAdewoyeAHMcMahonLCFarrerLATaylorJGKatoGJGladwinMTSteinbergMH. A network model to predict the risk of death in sickle cell disease. Blood2007; 110: 2727–35.
60.
SteinbergMHBartonFCastroOPegelowCHBallasSKKutlarAOrringerEBellevueROlivieriNEckmanJVarmaMRamirezGAdlerBSmithWCarlosTAtagaKDeCastroLBigelowCSaunthararajahYTelferMVichinskyEClasterSShurinSBridgesKWaclawiwMBondsDTerrinM. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003; 289: 1645–51.
61.
VoskaridouEChristoulasDBilalisAPlataEVarvagiannisKStamatopoulosGSinopoulouKBalassopoulouALoukopoulosDTerposE. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood2010; 115: 2354–63.
62.
Lobo CL deCPintoJFCNascimentoEMMouraPGCardosoGPHankinsJS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol2013; 161: 852–60.
63.
QuinnCTRogersZRBuchananGR. Survival of children with sickle cell disease. Blood2004; 103: 4023–7.
